Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA has about 200 pediatric supplements pending after eight approvals so far in 1997.

Executive Summary

FDA PEDIATRIC LABELING SUPPLEMENTAL APPROVALS TOTAL EIGHT IN 1997 from submissions to the agency from manufacturers in response to pediatric labeling regulations proposed in 1994. The agency estimated that approximately 200 pediatric supplements have been submitted in response to the regs, although it does not have an estimate of how many of those submissions contain data to support a new pediatric claim. Supplements were due at FDA under the 1994 rule in April. The Clinton Administration has interpreted the 1994 rule as an unsuccessful attempt to encourage appropriate pediatric labeling and issued a proposed rule to mandate pediatric studies on Aug. 13 ("The Pink Sheet" Aug. 18, p. 3-7).

Latest Headlines
See All
UsernamePublicRestriction

Register

PS030752

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel